Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL.

Biolcati, G; Hanneken, S; Minder, E I; Neumann, N J; Wilson, J H P; Wolgen, P J; Wright, D J; Lloyd, A J.

Afiliação

Biolcati G; Centre for Porphyrias, Istituto Dermatologico S. Gallicano - Istituti Fisioterapici Ospitalieri, Rome, Italy.
Hanneken S; Private Practice Empoderm, Düsseldorf, Germany.
Minder EI; Stadtspital Triemli, Porphyria Outpatient Clinics, Zurich, Switzerland.
Neumann NJ; Department of Dermatology, Heinrich Heine University, Duesseldorf, Germany.
Wilson JHP; The Department of Internal Medicine, Center of Lysosomal and Metabolic Diseases, Erasmus Medical Center, Rotterdam, Netherlands.
Wolgen PJ; Clinuvel Pharmaceuticals Limited, Melbourne, Australia.
Wright DJ; Clinuvel Pharmaceuticals Limited, Melbourne, Australia.
Lloyd AJ; Acaster Lloyd Consulting Ltd, London, UK. andrew.lloyd@acasterlloyd.com.

J Patient Rep Outcomes ; 5(1): 73, 2021 Aug 15.

Article em En | MEDLINE | ID: mdl-34396462

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article